Viking Therapeutics (VKTX) Net Equity Issued and Repurchased (2015 - 2018)

Viking Therapeutics has reported Net Equity Issued and Repurchased for 4 years, with the latest figure at $165.2 million in Q3 2018.

• Quarterly Net Equity Issued and Repurchased rose 13116.4% year-over-year to $165.2 million in Q3 2018, while the trailing twelve-month figure through Dec 2018 was $238.5 million (up 1072.06% YoY) and the FY2018 annual result came in at $296.6 million, up 1226.98% from the prior year.
• Net Equity Issued and Repurchased improved to $165.2 million in Q3 2018 per VKTX's latest filing, from $58.8 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $165.2 million in Q3 2018 and troughed at $25772.0 in Q3 2016.
• A 4-year average of $28.1 million and a median of $2.5 million in 2017 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2016 and 2018: Net Equity Issued and Repurchased tumbled 66.33% in 2016, then surged 13116.4% in 2018.
• Over 4 years, Net Equity Issued and Repurchased stood at $6.3 million in 2015, then slumped by 99.59% to $25772.0 in 2016, then surged by 56240.21% to $14.5 million in 2017, then jumped by 1037.78% to $165.2 million in 2018.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $165.2 million, $58.8 million, and $14.5 million for Q3 2018, Q1 2018, and Q4 2017 respectively.